Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 9/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144721 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL19410782 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL37519 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL3963403 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL18262003 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL969822 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL7571747 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL7570925 | 0.91 | S1PR1 (0.47) | P2RY10GPR34 | |
| SCHEMBL7203823 | 0.91 | PLA2G2C (0.36) | PLA2G2CPLA2G2D | |
| SCHEMBL5312425 | 0.87 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | GENZYME CORP (US) | 2026-05-21 | — | — | US | claimed |
| US-12419847-B2 | Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-09-23 | — | — | US | claimed |
| CN-119630637-A | Ionizable cationic lipids and lipid nanoparticles and methods of synthesis and use thereof | 潮汐疗法公司 | 2025-03-14 | — | — | CN | claimed |
| US-20240325327-A1 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | TRUSTEES OF DARTMOUTH COLLEGE | 2024-10-03 | — | — | US | claimed |
| US-20240325359-A1 | ACAT1 INHIBITOR AND METHOD OF USE IN THE TREATMENT OF DISEASE | TRUSTEES OF DARTMOUTH COLLEGE | 2024-10-03 | — | — | US | claimed |
| US-20240252678-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-01 | — | — | US | claimed |
| EP-4401782-A1 | SYNTHETIC EXOSOMES (SE) FOR CNS DELIVERY OF CRISPR FOR GENE EDITING IN BRAIN DISORDERS | The Regents of University of California (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2023240156-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF | TIDAL THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| EP-3843705-B1 | PREPARATION OF NANOSUSPENSION COMPRISING NANOCRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENTS WITH LITTLE OR NO STABILIZING AGENTS | CENTRE NAT RECH SCIENT (FR) | 2023-11-29 | — | — | EP | claimed |
| CN-117015374-A | Ionizable cationic lipids and lipid nanoparticles and methods of synthesis and use thereof | 潮汐疗法公司 | 2023-11-07 | — | — | CN | claimed |
| WO-2016037169-A1 | METHODS AND BIOCOMPATIBLE COMPOSITIONS TO ACHIEVE SUSTAINED DRUG RELEASE IN THE EYE | INTEGRAL BIOSYSTEMS LLC (US) | 2016-03-10 | — | — | WO | claimed |
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | University of Georgia Foundation, Inc. (US) | 2014-10-09 | — | — | US | claimed |
| US-8193334-B2 | Polymer-encapsulated reverse micelles | THE BRIGHAM AND WOMEN'S HOSPITAL (US) | 2012-06-05 | — | — | US | claimed |
| US-20100203142-A1 | AMPHIPHILIC COMPOUND ASSISTED NANOPARTICLES FOR TARGETED DELIVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-08-12 | — | — | US | claimed |
| US-20100196482-A1 | POLYMER-ENCAPSULATED REVERSE MICELLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-08-05 | — | — | US | claimed |
| EP-2144600-A2 | POLY (AMINO ACID) TARGETING MOIETIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-01-20 | — | — | EP | claimed |
| EP-2136788-A1 | CANCER CELL TARGETING USING NANOPARTICLES | Bind Biosciences, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | claimed |
| WO-2008124639-A2 | POLY (AMINO ACID) TARGETING MOIETIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-16 | — | — | WO | claimed |
| WO-2008121949-A1 | CANCER CELL TARGETING USING NANOPARTICLES | BIND BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | AIFM1, BAX, BCL2 | PLA2G2C 3102/4885PLA2G2D 3784/4885P2RY10 4266/4885 |
| US-20100203142-A1 | AMPHIPHILIC COMPOUND ASSISTED NANOPARTICLES FOR TARGETED DELIVERY | ANXA6, ANXA3, ANXA5 | PLA2G2C 2029/4885PLA2G2D 844/4885P2RY10 4263/4885 |
| US-12419847-B2 | Composition and method for attenuating neuroinflammation, amyloidopathy and tauopathy | MAPT, LCAT, ACAT2 | PLA2G2C 987/4885PLA2G2D 843/4885P2RY10 2767/4885 |
| US-20100196482-A1 | POLYMER-ENCAPSULATED REVERSE MICELLES | PHAX, POLRMT, ABCB4 | PLA2G2C 1025/4885PLA2G2D 3487/4885P2RY10 4829/4885 |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | PLA2G2C 3769/4885PLA2G2D 3689/4885P2RY10 4651/4885 |
| US-20240325327-A1 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | MAPT, LCAT, ACAT2 | PLA2G2C 1980/4885PLA2G2D 1642/4885P2RY10 3372/4885 |
| US-20240325359-A1 | ACAT1 INHIBITOR AND METHOD OF USE IN THE TREATMENT OF DISEASE | ACAT2, ACAT1, LCAT | PLA2G2C 1881/4885PLA2G2D 2615/4885P2RY10 4469/4885 |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | CD2BP2, CD2, CD4 | PLA2G2C 101/4885PLA2G2D 208/4885P2RY10 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.